Holen Sie sich die Stockscreener-App
6.08
1.30%
-0.08
Handel nachbörslich:
6.15
0.07
+1.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$6.16
Offen:
$6.11
24-Stunden-Volumen:
2.55M
Relative Volume:
1.03
Marktkapitalisierung:
$2.25B
Einnahmen:
$9.47B
Nettoeinkommen (Verlust:
$-178.00M
KGV:
-12.67
EPS:
-0.48
Netto-Cashflow:
$1.01B
1W Leistung:
+7.42%
1M Leistung:
-17.95%
6M Leistung:
-8.71%
1J Leistung:
-4.55%
1-Tages-Spanne:
$5.97
$6.20
1-Wochen-Bereich:
$5.62
$6.305
52-Wochen-Spanne:
$4.25
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.08 | 2.28B | 9.47B | -178.00M | 1.01B | -0.48 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Idahoans may be eligible for money from generic drug settlement - KMVT
Idaho joins $17.85M settlement over alleged generic drug price-fixing - KTVB
$17.85 Million in Settlements in Ongoing Generic Drug Price-Fixing Conspiracy Cases - Big Country News
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Bausch + Lomb CEO: Standing still is the new falling behind - Fortune
10 students living with GI disease to get up to $10K for school - Stock Titan
Bausch Health Cos (BHC) to Release Earnings on Wednesday - MarketBeat
AG settlements with Lannett and Bausch $17M - Oregon Business Report
Future of Ion Channel Modulators Market Growth (2026-2033) | - openPR.com
Scar Treatment Market Expected See Incredible Growth - openPR.com
Is Bausch Health (BHC) Pricing Reflect Long Term Potential After 81% Five Year Share Slump - Sahm
Migraine Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | GSK, Merck, Pfizer, Bausch Health, Amgen, Abbvie AstraZeneca, Eli Lilly and Co - Barchart.com
The Truth About Bausch Health Companies: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch HealthLupin | Press Release - lupin.com
AG Drummond reaches settlement with drug companies accused of price-fixing - fox23.com
The Bull Case For Bausch Health Companies (BHC) Could Change Following Failed Xifaxan RED-C Trials Learn Why - Yahoo Finance
Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to "Strong-Buy" - MarketBeat
Are you eligible to receive a portion of $17 million pharmaceutical settlement? - FourStatesHomepage.com
Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results - Finviz
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail
CT Prescription Buyers Could See Refunds In $17.9M Drug Price-Fixing Settlement - AOL.com
Quarterly Earnings: Is HGBL in a long term uptrendTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com
Michigan AG Secures $17.85M in Settlements with Lannett, Bausch Over Generic Drug Price-Fixing Allegations - Hoodline
Nebraska Attorney General’s Office Announces Settlements with Lannett and Bausch Totaling $17.85 Million Over Conspiracies to Inflate Prices and Limit Competition - chadronradio.com
Maryland Announces $17.85 Million Settlement in Drug Pricing Case - The MoCo Show -
Maryland Attorney General announces $17.85 million settlements with generic drug manufacturers - nottinghammd.com
Analyst Downgrade: Is now the right time to enter ADNT2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention - Finviz
Bausch Health Companies Inc. (BHC): Investor Outlook With A 28.97% Potential Upside - DirectorsTalk Interviews
AG Jennings Secures $17.85-million Settlement with Lannett and Bausch; Compensation Possible - WGMD
Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz - NCDOJ (.gov)
How to get compensation after DC, Md. and Va. settle $17.85M drug price fixing lawsuit - WJLA
South Dakota settles with two generic drug companies; Joins lawsuit against a third - DRGNews
Attorneys general across the U.S, including Illinois, reach nearly $18 million drug settlement - cbsnews.com
Lannett and Bausch reach $18M drug price-fixing settlement with states - Crain's New York Business
Colorado and coalition strike a deal with drug companies accused of price-fixing - Colorado Public Radio
Arizona AG announces settlements over generic drug prices - KTAR News 92.3 FM
South Dakota joins settlements totaling $17.85 million over generic drug price fixing - KOTA Territory News
AG Sunday Announces $17.85M National Settlement Over Generic Drug Price-Fixing; Pennsylvanians are Eligible for Compensation - attorneygeneral.gov
Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement - USA Herald
South Dakota Attorney General Jackley Announces Settlement With Two Generic Drug Companies - South Dakota State News (.gov)
Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal - Law360
Attorney General Tong Announces Settlements With Lannett and Bausch - CT.GOV-Connecticut's Official State Website (.gov)
Has The Market Gone Too Far In Marking Down Bausch Health (BHC) Shares? - Yahoo Finance
Bausch Health Trial Miss Puts Liver Program And Valuation In Focus - Yahoo Finance
Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC) - simplywall.st
Institutional Investors May Adopt Severe Steps After Bausch Health Companies Inc.'s (NYSE:BHC) Latest 15% Drop Adds to a Year Losses - 富途牛牛
Earnings Beat: How do insiders feel about Central Plains Bancshares IncPortfolio Performance Summary & Growth Focused Entry Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring A 28% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):